PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.
Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.
Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Singapore, Singapore
To evaluate additional pharmacodynamic markers in response to multiple oral doses of PF-04620110.
Time frame: Day 1 to Day 13
To evaluate secondary Pharmacodynamic Endpoints in response to a liquid meal test in response to multiple oral doses of PF-04620110.
Time frame: Day 6 and Day 14
To characterize the PK of PF-04620110 following multiple oral doses in otherwise healthy overweight and obese subjects.
Time frame: Baseline to 2 weeks
To assess safety and tolerability of PF-04620110 will be assessed by physical examinations, adverse event monitoring, 12-lead ECGs, vital sign, and clinical safety laboratory measurements.
Time frame: Baseline to 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.
Multiple oral doses of placebo will be given once daily for 2 weeks.